Comparing the current results to its competitors, Omeros reported Revenue increase in the 2 quarter 2026 by 387.1 % year on year. The sales growth was above Omeros's competitors' average revenue growth of 38.38 %, achieved in the same quarter.
Omeros's Comment on Competition and Industry Peers
The pharmaceutical and biotechnology industry includes both large established companies and smaller firms competing in areas such as product effectiveness, safety, cost, research and development capacity, manufacturing capabilities, and financial resources. Daiichi Sankyo is identified as a competitor in relation to patent rights reversion.
December 19, 2024
Omeros Achieves Pivotal Milestone with Narsoplimab in TA-TMA Treatment In a groundbreaking announcement, Omeros Corporation (Nasdaq: OMER) revealed that its lead investigational therapy, narsoplimab, has successfully met the primary endpoint in a pivotal trial for treating thrombotic microangiopathy (TA-TMA) associated with hematopoietic stem cell transplants (HSCT). This first-in-class monoclonal antibody specifically inhibits the lectin pathway of the complement system, a critical process implicated in the development of TA-TMA a life-threatening condition that often emerges post-HSCT in both adult and pediatric populations.The results of an independent statistical review confirmed that narsoplimab demonst...
August 8, 2024
: Omeros Corporation, a biopharmaceutical company focused on therapeutics for immunologic disorders, has announced significant financial results and corporate developments for the second quarter of 2024. This article synthesizes the company s recent performance indicators, strategic financial maneuvers, and expected announcements, emphasizing their implications for future clinical and commercial activities. Omeros Corporation (Nasdaq: OMER), based in Seattle, is dedicated to the discovery and development of therapeutics addressing major and orphan diseases, particularly those related to immunologic disorders, cancer, and addiction. As the company traverses the clinical landscape, recent financial disclos...
August 7, 2024
Seattle-based biotech company strengthens its balance sheet and prepares for potential commercialization. Recent Financial Performance: Second Quarter 2024 SEATTLE Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical firm renowned for its pioneering work in small-molecule and protein therapeutics designed to target immunologic disorders, cancers, and addictive/compulsive disorders, has unveiled its financial results for the second quarter ended June 30, 2024.The Q2 2024 results underscore Omeros’ financial resilience and strategic focus on accelerating its high-impact clinical programs. In addition to its extensive research and development efforts, the firm has revealed multiple key h...
May 9, 2024
Omeros Corporation (Nasdaq: OMER), a renowned biopharmaceutical company, recently announced that interim analysis data from its ongoing Phase 2 study of OMS906, an investigational inhibitor of MASP-3, has been selected for podium presentation at the 2024 European Hematology Association (EHA) Hybrid Congress. This development marks a significant milestone in the company s efforts to address paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. The congress is scheduled to take place from June 13 to 16, 2024, in Madrid, Spain.Presentation of Interim Analysis Data:Omeros Corporation s ongoing Phase 2 study aims to evaluate the effectiveness and safety of OMS906 in patients with PNH. The interim anal...
Zymeworks Inc is a biotechnology company that operates on a licensing and collaboration business model. They primarily generate revenue through partnerships and collaborations with pharmaceutical and biotechnology companies, providing access to their proprietary drug development platform and expertise in protein engineering. This enables them to advance the development of novel bi-specific antibodies and therapeutic proteins for the treatment of various diseases and medical conditions.
Pliant Therapeutics Inc operates with a business model focused on developing novel therapeutics to address fibrotic diseases. The company conducts extensive research to identify and target specific molecular pathways involved in fibrosis, with the aim of developing effective treatments. Pliant Therapeutics collaborates with academic institutions and conducts preclinical and clinical studies to bring its products to market and improve the lives of patients suffering from fibrotic conditions.
Phio Pharmaceuticals Corp's business model revolves around developing and commercializing innovative RNA-based therapeutics to treat various diseases and improve patient outcomes.
NextCure Inc is a biopharmaceutical company that operates with a unique business model. They focus on discovering and developing novel immunomedicines to treat various forms of cancer and other immune-related diseases. With a focus on developing innovative therapies that target immune cells, NextCure aims to provide effective and personalized treatment options for patients in need.
Sources:
Omeros Corporation’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Omeros Corporation versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
